Bottom line
"Using drugs to slow aging" is a spectrum. At one end, statins for preventing cardiovascular disease rest on 26 randomized trials and about 170,000 people: each 1.0 mmol/L drop in LDL cholesterol cut major vascular events by about one fifth per year, with no bend where "lower was too low." 10 At the other end, mouse lifespan experiments are only now producing a first batch of signals. 3
GLP-1 drugs, a class first used to lower glucose and body weight, sit in the middle of the spectrum. They took diabetes and obesity first, then gained approvals for cardiovascular disease, chronic kidney disease, obstructive sleep apnea, and metabolic fatty liver disease. 2 Whether they directly slow aging, in one reading, is this: one mouse study gave a positive signal, but it used only female mice, the control group's lifespan ran short, and food intake also fell by about a quarter. The discount has to be large. 314
The metformin signal comes from people with diabetes: users had lower all-cause mortality than non-users. 11 The same topic page also includes a newer analysis of more than 230,000 people that did not see a survival advantage. 8 The mechanism is still unclear, and the drug blunts part of the benefit exercise brings. 8
Rapamycin has the most straightforward mechanism — it specifically inhibits the mTOR pathway — but human trials have only just started, and they are small and short. 413
The shared floor of the views: a drug is a lever that comes after sleep, exercise, and nutrition. 6
What it is
Two conversations have to be split. One is a new approved use: GLP-1 drugs built for metabolic disease were later approved for cardiovascular disease and kidney disease. 2 The other is acting on aging itself, pushing several diseases of old age back together. The field calls that an aging intervention.
One account cites a two-axis map for placing these drugs: is the mechanism known or unknown, and is there a biomarker? 4
A statin is the model student. Which enzyme it inhibits is clear, and LDL cholesterol is a marker that can measure the effect. 4
Rapamycin's mechanism is clear too. It is a specific inhibitor of mTOR, and the degree of biochemical inhibition can be measured. What is missing is an agreed answer to "how much inhibition corresponds to how much anti-aging benefit." 4
Metformin occupies neither end. People still cannot say clearly how it works. AMPK activation — AMPK is an enzyme cells use to sense energy status — inhibition of mitochondrial complex 1, and gut bacteria metabolizing folate have all been proposed. 48
One aging topic page supplies another piece of the background. Cellular senescence: after a cell loses the ability to divide, it secretes inflammatory signals that spill onto neighbors, speeds the failure of tissue, and is tied to arthritis, cardiovascular disease, and some cancers. 5
The mTOR pathway that rapamycin acts on is critical for cell growth, repair, and healing. 9
Why it matters
Diseases of old age dominate death late in life, and pushing the whole onset later is a more attractive idea than treating one disease at a time.
The GLP-1 story is a living example. It started in diabetes, and the approved uses ran on to the heart and vessels, the kidney, sleep apnea, and fatty liver. Substance-use disorders are now under study as well. 2
One account notes that a trial can show "it works" and usually cannot answer "why it works." Did the benefit come from the weight loss itself, or from a direct effect of the drug on vessels and inflammation? That decides whether it counts as a true anti-aging drug. 2
For a healthy person the risk is asymmetric. The benefit is a hypothesis. The side effects arrive first. Known costs of rapamycin include mouth inflammation, a low white-cell count, less appetite, anemia, fatigue, higher blood lipids, and suppressed muscle-protein synthesis. 9
A gray market has not waited for the science to finish. In an interview, practicing physician Koniver described clinics already using peptides, hormones, and GLP-1 drugs for "longevity optimization." The conversation kept returning to the point that this has to be done by a clinician who knows the territory. 7
Biological-age tests are often cast as the referee of "whether the drug worked." That is exactly what the whole field lacks. Aging itself has no agreed outcome marker. 46
Different perspectives
Main positions
Drugs are one of five longevity domains in one public frame. The entrance is the usual three questions: goal, biomarker, and the balance of risk and benefit. 1
In a discussion of a clean drug and a dirty drug, the anti-aging drug space is laid open. A statin has a clear mechanism and a perfect marker. Rapamycin has a clear mechanism and a missing marker. Metformin lacks both. So do supplements such as NMN and NR. 4
The conclusion: the field is not tidy. The statin standard cannot be imagined onto the other drugs. 4
On the expanding uses of GLP-1 drugs, the question is not what else a drug can treat. It is why it can treat that. Trial designs usually cannot answer, so the clues are the people enrolled, how fast the effect appears, and how the benefit scales with the weight loss. 2
On semaglutide slowing aging in mice, one close read is on record. Median lifespan was about 12% longer, with three limits: only females, a control lifespan shorter than is common for the strain, and about a quarter less food. 3 A direct comparison with eating less had no lifespan endpoint. Eating less explained part of the functional tests, but spatial memory, exploration, and glucose control improved in the drug group beyond the restricted-food group. 3
What counts is replication in an independent cohort, not an imperfect cross-study comparison. 3
Another aging topic page lays the background at the level of the cell. Aging is driven by mechanisms such as telomere shortening, oxidative stress, and DNA methylation. Senescent cells secrete inflammatory signals and speed the failure of their neighbors. 5
When that page talks about longevity practices, the ones it names are dietary adjustment, strength and aerobic exercise, restorative sleep, stress management, and social connection. 5
In the Koniver episode, what is already happening in practice is put on the table. GLP-1 drugs, peptides such as BPC-157, growth-hormone-related peptides, testosterone therapy, NAD and its precursors, and methylene blue are all on the actual menu of longevity clinics. 7
What the episode stresses: these are prescription-level tools. Sourcing, safety monitoring, and finding a clinician who knows the territory are premises that cannot be skipped. 7
In a long conversation, the research on NAD, NMN, NR, rapamycin, and resveratrol is walked through, along with whether a biological-age test can serve as referee. 6 The landing place is the same. Sleep, nutrition, and exercise come first. Supplements come after. 6
A metformin topic page is one of the fullest public reviews of the drug.
On mechanism the page is frank. Complex 1 inhibition, a change in the AMP/ATP ratio, AMPK activation, and mTOR inhibition have all been proposed, and the line that people still do not know how metformin actually works has a place in what is cited. 8
Species evidence is spread out. Lifespan lengthened in worms, not in flies, and mouse results do not agree. 8
Both sides of the human signal are set out. In an observational study of about 78,000 people with diabetes taking metformin, survival was about 38% longer than in people taking a sulfonylurea, and about 15% longer than in people without diabetes who were not on the drug. 8 A newer analysis of more than 230,000 people did not see a survival advantage from metformin. 8 Pooled systematic reviews still support lower all-cause mortality among metformin users, and that is the starting point of the anti-aging-effect hypothesis. 11
The exercise-interference evidence is included too. Used together with exercise, improvements in vascular insulin sensitivity and blood flow were blunted, and part of the adaptation to resistance training was discounted. 8
On the rapamycin page the stance is more cautious. After an improvement in heart function in dogs, later work could not repeat it. The page attributes that to a lower amount, a smaller sample, younger dogs, and a test that was not sensitive enough. Marmosets tolerated it safely and showed no lifespan effect. 9
The closing line: whether rapamycin can slow human aging is still fiercely debated, and worries about long-term safety are unresolved. 9
Where views agree and differ
Four points of agreement.
A mechanism is not human evidence of a longer life. Metformin is the clearest half-solved puzzle. 48
Behavior comes first. A drug is a later lever. 156
Any drug needs a goal, a marker, and a recheck. 14
Gray markets and self-medication are not the path. Prescription-level tools stay in a clinician's hands. 7
Two points of difference.
One is which example each account chooses. One keeps the clearest example for the statin: which enzyme, and which lipid marker tracks it, are both explicit. 4 Rapamycin, in that account, has only a clear mechanism and no agreed marker of an aging effect. 4 Another places both metformin and rapamycin in a middle state, where population signals and small human trials sit together. 89
The other is where the narration sits. One discussion lays open what practice already looks like — what clinics are already using. 7 Another is busy teaching an audience how to read evidence. 23 A further account is busy making mechanisms and species differences clear. 8
PearHealth's synthesis
We re-order the spectrum by strength of evidence.
The firmest layer is "lowering lipids to prevent cardiovascular events." The statin benefit holds in a meta-analysis of randomized trials, and it does not depend on an "anti-aging" frame. 10
The middle layer is "approved uses still expanding." Each new GLP-1 use has its own trial, and "it slows aging itself" is still a hypothesis. The mouse data are worth reading cold, against that list of limits. 2314
A weaker layer is "a signal for a new use of an old drug." The population association for metformin looks striking. Mechanism and trials have not caught up, and interference with exercise has to be counted as a cost. 811
The weakest layer is "a drug aimed directly at aging." Human evidence for rapamycin is only small trials such as PEARL, and the side-effect pattern is known. 139
Nothing here is advice to use a prescription drug. It belongs in a conversation with one's own clinician. 1
How strong is the evidence
A meta-analysis packs similar randomized trials together, and that is where the statin conclusion comes from. Twenty-six trials, about 170,000 people: for each 1.0 mmol/L drop in LDL cholesterol, major vascular events fell by about one fifth, and cancer incidence did not rise. 10
Registration trials for new approved uses are the foundation of the GLP-1 expansion. Each use has its own confirmatory trial, and the attribution of mechanism is still open. 2
Population cohorts support the metformin signal. Lower mortality among users is an observational result, open to confounding of the kind "people who can get metformin were healthier to begin with." 811
Small trials in older adults have only just started. A randomized trial of 264 older adults used a combination of two mTOR inhibitors — not rapamycin — and infections fell. 12 The trial that used intermittent low-amount rapamycin directly is PEARL. It ran nearly a year. Adverse events were similar to the placebo group, visceral fat did not change, and some questionnaire measures improved. 13
Mouse studies supply a direction, not an answer. Median lifespan in female mice was about 12% longer. The control lifespan ran short, and the animals also ate less, so the reading takes a large discount. 314
Enthusiasm for a drug that rests only on personal experience is not evidence. 67
What you can do
- Use the levers that do not depend on a drug first: lipids, glucose, blood pressure, not smoking, exercise, sleep. 156
- Walk into the visit with markers: apolipoprotein B, HbA1c, liver and kidney function, so a drug conversation has a starting point. 1
- Any report of "a new use for an old drug" is a prompt to ask whether there is a human trial, how long it ran, and who was in it. 3
- Do not buy prescription drugs online, and do not touch peptides or "longevity shots" of unclear origin. 7
- People on a drug for a long time recheck the related markers on the schedule a clinician sets. For a statin, that often means liver tests and creatine kinase. For metformin, kidney function and vitamin B12. 89
Questions worth raising with a clinician:
- Given my cardiovascular risk, what level is a drug being asked to reach? 10
- Could a drug I am taking affect what I get from exercise? 8
- I saw a study of an "anti-aging drug" and I want your reading of it. 3
Common misconceptions
Misconception one: a longer life in a mouse means a longer life in a person. In practice, species differences, the conversion, and replication are all gates. Lifespan results for metformin do not agree across worms, flies, and mice, and rapamycin has its own limits in dogs and marmosets. 89
Misconception two: a drug used for decades is therefore safe. The people it is used in have changed, and the risk ledger has to be recalculated. Rapamycin's effects on blood lipids and on muscle synthesis are costs sitting in plain sight. 9
Misconception three: a biological-age test can judge whether an anti-aging drug works. Aging itself has no agreed outcome marker, and the other side of the conversation in the show notes agrees. 4
Misconception four: approved uses that keep expanding mean it can treat anything. Each new use needs its own trial. "It seems to treat everything" is more likely the same metabolic benefit showing up again in different diseases. 2
Misconception five: if it can be bought online, it can be used on one's own. Koniver kept returning to the premise: a clinician who knows the territory, and safety monitoring. 7
How it connects to your blood work
No blood test measures "how fast someone is aging." Each drug on this spectrum has markers of its own to watch.
- Apolipoprotein B (apob) and LDL cholesterol (ldl-c): the direct scale for a statin and for a lipid-lowering target. One account has shown using them to define a drug question. 14
- HbA1c (hba1c) and fasting glucose (fasting-glucose): baseline and follow-up markers for metabolic drugs such as GLP-1 drugs and metformin. 8
- Alanine aminotransferase (alt) and creatine kinase (ck): often used to watch liver and muscle in people on a statin for a long time.
- Estimated glomerular filtration rate (egfr): a kidney-function check before and after metformin is used.
- Vitamin B12 (vitamin-b12): people on metformin for a long time tend to run low, and a periodic check is worth doing. 8
- Triglycerides (triglycerides): rapamycin is known to push blood lipids up, so people using it watch this. 9
- Lipoprotein(a) (lp-a): a lipid marker set mostly by genes. It helps judge how much residual risk a lipid-lowering strategy still leaves.